BerGenBio AS Selects Sygnature Discovery for BGB002 Drug Development
10/8/2012 11:27:58 AM
More...
|
BerGenBio AS Completes $9 Million Series A Financing for First in Class Oncology Therapeutics
1/9/2012 7:28:02 AM
More...
|
Promising Prognostic and Preclinical Data for Acute Myeloid Leukemia and BerGenBio AS’s BGB324 at American Society of Hematology
12/7/2011 6:25:37 AM
More...
|
BerGenBio AS Initiates Preclinical Development of Novel AXL Inhibitor BGB324
10/31/2011 7:03:11 AM
More...
|